Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, January 31, 2015
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
ProImmune Introduces ProM2™ Human Class II MHC Monomer Reagents
Friday, January 30, 2015
Enabling proven tetramer analysis for detecting single antigen-specific T cells.

Bringing Customers a New Web Experience - Alfa Aesar Launches Redesigned Website
Thursday, January 29, 2015
The redesign provides a fresh new layout and offers improved intuitive navigation with a high degree of user-friendliness.

Irvine Scientific Introduces PRIME-XV® T Cell Culture Medium
Wednesday, January 21, 2015
A xeno-free and serum-free medium for immunotherapy applications.

Specificity-Verified Monoclonal Antibodies
Friday, January 16, 2015
Ultraspecific and extensively validated monoclonal antibodies from AMSBIO.

Ebola Antigens and Antibodies for ELISA
Friday, December 19, 2014
AMSBIO products for the development of an ELISA detection assay for the Ebola virus.

Imperial Innovations Leads £50 Million Series B Funding Round in Cell Medica
Tuesday, November 25, 2014
Cell Medica will use the investment capital to progress further the development of cellular immunotherapy products.

Merck Millipore Launches Kit for Analyzing NF?B Translocation
Thursday, November 20, 2014
Permits quantitative, statistically robust assessment of NF?B translocation.

Agilent Introduces New Column Innovations for Biotherapeutics Development
Thursday, November 13, 2014
Reversed-phase columns optimized to separate monoclonal antibodies.

Merck Millipore's New SNAP i.d.® 2.0 System for Immunohistochemistry
Friday, November 07, 2014
Offers parallel processing of up to 24 slides at once, without the cost of automation.

<< 1 2 3 4 5 6 7 >>
Showing Results 1 - 10 of 373
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
SELECTBIO
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn